David Brassat

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event

Darin T. Okuda, Orhun H. Kantarci, Matilde Inglese et al. · PLoS ONE · 2014 · 332 citations · Full text

Medicine, Neurology, Neuroscience +15

Neuromyelitis optica in France

Nicolas Collongues, Romain Marignier, Hélène Zéphir et al. · Neurology · 2010 · 211 citations

Medicine, Neurology, Neuro-ophthalmology +13

Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes

Ester Cantó, Mar Tintoré, Luisa María Villar et al. · Brain · 2015 · 191 citations · Full text

Life Sciences, Clinical Sciences, Neurology +15

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis

Geoffrey Hinsinger, Nicoletta Galeotti, Nicolas Nabholz et al. · Multiple Sclerosis Journal · 2015 · 183 citations

Life Sciences, Neurology, Neuroscience +17